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The membrane-anchored ubiquitin ligase gp78
promotes degradation of misfolded endo-
plasmic reticulum (ER) proteins and sterol-
regulated degradation of HMG-CoA reductase.
It was known previously that Ufd1 plays a criti-
cal role in ER-associated degradation (ERAD)
together with Npl4 and VCP. The VCP-Ufd1-
Npl4 complex recognizes polyubiquitin chains
and transfers the ubiquitinated proteins to the
proteasome. Here we show that Ufd1 directly
interacts with gp78 and functions as a cofactor.
Ufd1 enhances the E3 activity of gp78, accel-
erates the ubiquitination and degradation of
reductase, and eventually promotes receptor-
mediated uptake of low-density lipoprotein.
Furthermore, we demonstrate that the monou-
biquitin-binding site in Ufd1 is required for the
enhancement of gp78 activity and that the poly-
ubiquitin-binding site in Ufd1 is critical for a
postubiquitination step in ERAD. In summary,
our study identifies Ufd1 as a cofactor of gp78,
reveals an unappreciated function of Ufd1 in the
ubiquitination reaction during ERAD, and illus-
trates that Ufd1 plays a critical role in choles-
terol metabolism.
INTRODUCTION
The endoplasmic reticulum (ER) is the major organelle for
protein synthesis, folding, and assembly in the secretory
pathway. The maturation of proteins in the ER is not a per-
fect process. Eukaryotic cells have evolved a highly con-
served ER quality-control system, termed ER-associated
degradation (ERAD), to prevent the accumulation of termi-
nally misfolded proteins (Hampton, 2002). ERAD is the
pathway that directs misfolded polypeptides to proteaso-
mal degradation, thereby protecting cells from the dam-
age caused by the accumulation of these improperlyCelfolded proteins. The processes of ERAD include recogni-
tion of the ‘‘lesion’’ on misfolded proteins, polyubiquitina-
tion, dislocation from ER to cytosol, and delivery to the
proteasome for destruction (Meusser et al., 2005; Tsai
et al., 2002; Carvalho et al., 2006; Denic et al., 2006). Re-
cent studies have suggested that some of these steps are
tightly coupled together (Neuber et al., 2005; Younger
et al., 2006; Schuberth and Buchberger, 2005; Song
et al., 2005b). However, how these events in ERAD are
organized has remained obscure.
Ubiquitin fusion degradation 1 (Ufd1) protein is one of
the essential components of ERAD and plays a key role
in the degradation of misfolded proteins (Johnson et al.,
1995). In most circumstances, Ufd1 forms a complex
with Npl4 and the AAA ATPase VCP (also known as p97
or Cdc48) to transfer the ubiquitinated proteins to the pro-
teasome (Meyer et al., 2000; Ye et al., 2001, 2003; Bays
and Hampton, 2002; Meyer et al., 2002). Dislocation
across the ER membrane into the cytoplasm is a process
that requires energy. The VCP-Ufd1-Npl4 complex has
been proposed to form a ring-like structure around the
substrates and provides the driving force for dislocation
(DeLaBarre and Brunger, 2003; Pye et al., 2007). The
COOH-terminal one-third portion of Ufd1 binds both
Npl4 and VCP at different sites (Bruderer et al., 2004;
Pye et al., 2007). In addition, Ufd1 binds polyubiquitin
chains via its NH2-terminal domain, and this binding is
synergistically enhanced by VCP (Ye et al., 2003). Deletion
of the NH2-terminal domain of Ufd1 results in the blockage
of ERAD (Ye et al., 2003), indicating that the polyubiquitin
binding of Ufd1 is required for ERAD. However, a recent
structural study has revealed that the NH2-terminal do-
main of Ufd1 comprises two independent binding sites
for mono- and polyubiquitin, respectively (Park et al.,
2005). These sites’ individual functions in ERAD are largely
unknown.
The enzyme 3-hydroxy-3-methylglutaryl coenzyme A
reductase (HMG-CoA reductase) catalyzes the reduction
of HMG-CoA to mevalonate, a rate-limiting step in the syn-
thesis of cholesterol (Goldstein and Brown, 1990). The sta-
bility of HMG-CoA reductase is tightly regulated in cells:
HMG-CoA reductase protein is degraded through ERAD
pathway in the presence of high levels of sterol (Severl Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 115
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRFigure 1. Identification of Ufd1 as
a gp78-Associated Protein
(A) gp78 complex was immunoprecipitated
with anti-gp78-coupled agarose from HEK293
cells as described in Experimental Procedures.
The eluted proteins were subjected to SDS-
PAGE and stained with colloidal blue. Proteins
identified by mass spectrometry are indicated.
The results shown are representative of two
independent experiments.
(B) CHO-7 cells were harvested, lysed, and
subjected to immunoprecipitation with anti-
gp78 or anti-GFP (control). Aliquots of the su-
pernatant and pellet (5-fold of the supernatant)
fractions of immunoprecipitates were sub-
jected to SDS-PAGE. Immunoblot (IB) analysis
was carried out with the indicated antibodies.
(C) CHO-7 cells were transfected with the indi-
cated expression plasmids. Twenty-four hours
after transfection, cells were harvested, lysed,
and subjected to immunoprecipitation with
anti-FLAG (against Ufd1). Immunoblot analysis
was carried out with the indicated antibodies.
The asterisk denotes a crossreactive band.
Results shown in (B) and (C) are representative
of three independent experiments.et al., 2003; Song et al., 2005a). This is one of the regula-
tory pathways that cells employ to feedback control the
synthesis of cholesterol (Brown and Goldstein, 1980).
Mammalian HMG-CoA reductase has two distinct do-
mains: the NH2-terminal membrane domain with eight
transmembrane helices, and the COOH-terminal cytosolic
domain that exerts all of the catalytic activity of the en-
zyme (Liscum et al., 1985; Roitelman et al., 1992). The
membrane domain of reductase mediates sterol-induced
ubiquitination and degradation (Gil et al., 1985; Skalnik
et al., 1988). Our previous study determined that gp78,
a membrane-anchored ubiquitin ligase, catalyzes the ste-
rol-induced ubiquitination of HMG-CoA reductase (Song
et al., 2005b). gp78 interacts with VCP and a membrane
protein, Insig-1 or -2. Sterol promotes reductase to bind
to Insig-1/2 through its membrane domain, thereby form-
ing a quadruple complex containing reductase, Insig-1/2,
gp78, and VCP. gp78 catalyzes the ubiquitination of
reductase at specific lysine residues (Sever et al., 2003).
After ubiquitination, gp78-associating VCP appears to
mediate the degradation of reductase (Song et al., 2005b).
To further understand the mechanism of ERAD of HMG-
CoA reductase stimulated by sterol, we utilized affinity
purification coupled with mass spectrometry to identify
gp78-interacting proteins, and our results revealed Ufd1.
We show that Ufd1 directly binds to gp78, potentiates
its E3 activity in vitro, increases ubiquitination and degra-
dation of HMG-CoA reductase in vivo, and thereby regu-
lates the receptor-mediated uptake of low-density lipo-
protein (LDL). Mutation of the mono- but not the
polyubiquitin-binding site in Ufd1 abolishes the enhance-
ment of gp78 activity by Ufd1. In summary, the current
results identify Ufd1 as a cofactor of gp78, reveal an116 Cell Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inunappreciated function of Ufd1 in the ubiquitination reac-
tion during ERAD, and find that Ufd1 plays a critical role in
cholesterol metabolism. Together with the previous find-
ings on Ufd1, our results indicate that Ufd1 has a dual
role in ERAD: increasing E3 activity and mediating the
postubiquitination step.
RESULTS
Ufd1 Interacts with gp78
To identify proteins associated with gp78, we raised
antibodies against the cytosolic domain of gp78. Affinity-
purified anti-gp78 antibody was used to immunopurify the
gp78 complex from the detergent-solubilized membrane
fraction of HEK293 cells. Proteins eluted from anti-gp78-
coupled beads were subjected to SDS-PAGE, visualized
with colloidal blue staining, and identified by tandem
mass spectrometry. Of the proteins we identified, VCP
and UBE2G2 (also called Ubc7) have been previously
shown to directly interact with gp78 (Chen et al., 2006;
Song et al., 2005b; Ballar et al., 2006; Zhong et al.,
2004), which demonstrates that the method we used is
effective. One of these proteins, Ufd1, was chosen for
further study in this report (Figure 1A).
To confirm the interactions between Ufd1 and gp78, we
first performed a coimmunoprecipitation (coIP) experi-
ment to detect the interaction between endogenous pro-
teins. A detergent extract of CHO cells was subjected to
IP with control or anti-gp78 antibodies followed by immu-
noblot. The results showed that endogenous Ufd1 copre-
cipitated with gp78 (Figure 1B, top panel, lane 1) but was
absent in the pellet fraction of the control IP (top panel,
lane 2). We next carried out a coIP experiment to confirmc.
Cell Metabolism
Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRthe complex formation of transfected Ufd1 and gp78.
CHO cells were transfected with different combinations
of expression constructs, and 24 hr after transfection,
the cell lysate was prepared and subjected to IP with
anti-FLAG-coupled agarose to pull down FLAG-Ufd1.
gp78 was present in the pellet fraction of FLAG-Ufd1 IP
(Figure 1C, top panel, lane 6). Notably, Hrd1, another
membrane-anchored ubiquitin ligase bearing homology
to gp78 (Nadav et al., 2003; Kikkert et al., 2004), did not
coprecipitate with FLAG-Ufd1, although the expression
level of Hrd1 was similar to that of gp78 as shown in the
supernatant fraction (Figure 1C, third panel). Taken to-
gether, these results indicate that both endogenous and
transfected Ufd1 can form a complex with gp78.
Ufd1 Directly Interacts with the Middle Region of
gp78 through Residues 258–275
Both gp78 and Ufd1 have been shown to interact with VCP
directly (Zhong et al., 2004; Song et al., 2005b; Meyer
et al., 2000). To test the possibility that the gp78-Ufd1 in-
teraction is indirectly bridged by VCP, we carried out coIP
experiments using cells in which the expression of VCP
was knocked down by RNA interference (RNAi). As shown
in Figure S1 in the Supplemental Data available with this
article online, Ufd1 still coprecipitated with gp78 regard-
less of VCP RNAi (lanes 3–4). Immunoblotting revealed
that the expression of VCP protein was substantially re-
duced by RNAi (Figure S1).
Next, to gain more insights on the gp78-Ufd1 interac-
tion, the regions of gp78 and Ufd1 responsible for their in-
teraction were mapped. A series of constructs encoding
gp78 deletion mutants fused with Myc tags were cotrans-
fected with FLAG-Ufd1 construct into CHO cells. The cell
lysates were subjected to anti-Myc IP, and gp78 and Ufd1
were detected by immunoblot. Almost all gp78 fragments,
except for D383–578 and D383–497, were capable of
binding to Ufd1 (Figure 2B). The results, summarized in
Figure 2A, indicate that Ufd1 binds to gp78 at the region
between residues 383 and 497, which is different from
the VCP-interacting motif (aa 614–643) (Figure 2A) (Ballar
et al., 2006). Since the Ufd1-binding region in gp78 con-
tains a Cue domain that usually binds to ubiquitin or E2
(Biederer et al., 1997; Kang et al., 2003; Prag et al.,
2003), we next tested the binding of this Cue domain to
Ufd1, ubiquitin, and UBE2G2. As shown in Figure S2,
the separated Cue domain alone and its adjacent region
(aa 383–456) can interact with Ufd1 individually, although
the adjacent region shows stronger interaction, suggest-
ing that more than one discrete binding site may be pres-
ent in the aa 383–497 fragment. The Cue domain of gp78
alone efficiently binds to ubiquitin, but not to UBE2G2,
consistent with the previous study by Chen et al. (2006).
To identify the region of Ufd1 that interacts with gp78,
we transfected a series of constructs encoding FLAG-
tagged Ufd1 deletion mutants together with gp78-Myc
construct into CHO cells. The cell lysates were subjected
to anti-FLAG IP, and gp78 and Ufd1 were detected by
immunoblot. Our results showed that only the Ufd1 vari-
ants D215–302 and D258–275 could not bind to gp78Cell(Figure 2D). Collectively, the residues between 258 and
275 in Ufd1 are required for interaction with gp78 (summa-
rized in Figure 2C). This region in Ufd1 overlaps with the
Npl4-binding site, but not the VCP-binding site (Bruderer
et al., 2004). Interestingly, Ufd1(D8–119) and Ufd1(D120–
214) bind to gp78 better than full-length Ufd1 does
(Figure 2D). It is possible that the deletion of these regions
renders the gp78-binding site more readily accessible.
Next, we performed an in vitro GST pull-down assay to
demonstrate the direct interaction between gp78 and
Ufd1. We purified recombinant proteins from E. coli. First,
GST, GST-gp78c (cytosolic domain of gp78), and GST-
gp78c(D383–497) were immobilized on glutathione aga-
rose, and their bindings to His6-Ufd1 were tested. As
shown in Figure 2E, Ufd1 was capable of binding to the
gp78c fragment (lane 3), but not to the gp78c(D383–497)
fragment, which lacks the residues required for Ufd1 bind-
ing (lane 4). Similarly, Ufd1 directly bound gp78c in a con-
centration-dependent manner (Figure 2F, lanes 3 and 4).
However, Ufd1 lacking residues 258–275 failed to bind
to gp78c (Figure 2F, lanes 5 and 6). Taken together, these
data indicate that Ufd1 directly binds to gp78, and their
interacting sites have been identified.
Ufd1 Enhances the Ubiquitination and Degradation
of HMG-CoA Reductase In Vivo
Our previous studies have shown that gp78 interacts with
Insig-1 and -2 through its transmembrane domain (Song
et al., 2005b). Sterol promotes HMG-CoA reductase to
bind Insig; thereby, gp78 is recruited, ubiquitinates reduc-
tase at specific lysines, and causes reductase to be de-
graded by the proteasome (Sever et al., 2003). Two types
of sterols are known to stimulate the ubiquitination and
degradation of HMG-CoA reductase: the oxysterol 25-
hydroxycholesterol (25-HC) and the cholesterol precursor
lanosterol (Song et al., 2005a; Song and Bose-Boyd,
2004).
The experiment of Figure 3A was designed to determine
the effect of Ufd1 overexpression on sterol-regulated
ubiquitination of HMG-CoA reductase. After transfection
and sterol depletion, cells were treated with or without
25-HC in the presence of 10 mM MG132 (a proteasome in-
hibitor, to block protein degradation) for 3 hr. HMG-CoA
reductase was then immunoprecipitated, and its ubiquiti-
nation was analyzed. In the absence of Ufd1, 25-HC
modestly induced reductase ubiquitination (Figure 3A,
compare lanes 1 and 2). However, transfected Ufd1
dramatically enhanced 25-HC-induced ubiquitination of
reductase (Figure 3A, lane 4). Figure 3B shows that Ufd1
increased the ubiquitination of reductase in a concentra-
tion- and time-dependent manner.
We next performed a transfection experiment to deter-
mine the effect of Ufd1 on sterol-regulated degradation of
HMG-CoA reductase. Consistent with previous reports,
overexpressed reductase was not subject to sterol-
stimulated degradation (Figure 3C, lanes 1 and 2). This is
due to saturation of endogenous Insigs, as indicated by
restoration of sterol-regulated degradation when Insig-1
was cotransfected (Figure 3C, lanes 5 and 6) (SeverMetabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 117
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRFigure 2. Mapping of the Interaction Sites in gp78 and Ufd1
(A) Diagrammatic representation of gp78 and its truncated forms. Transmembrane helices (TM), RING-finger domain (RING), Cue domain, UBE2G2
binding region (G2BR), and the VCP-interacting motif (VIM) are indicated. The binding of gp78 variants to Ufd1 is summarized as positive (+) or
negative ().
(B) CHO-7 cells were transfected with the indicated constructs. Twenty-four hours after transfection, cells were harvested, lysed, and subjected to
immunoprecipitation with anti-Myc (against gp78). Immunoblot analysis was carried out with the indicated antibodies.
(C) Diagrammatic representation of Ufd1 and its variants. The binding of Ufd1 variants to gp78 is summarized as positive (+) or negative ().
(D) Immunoprecipitation was carried out with anti-FLAG (against Ufd1). Immunoblot analysis was performed with the indicated antibodies. The
asterisk denotes degraded bands.
(E and F) GST, His6-fused Ufd1 fragments, and various GST-fused gp78 fragments were individually generated in bacteria, purified, and incubated at
different combinations as indicated to perform GST pull-down assays. Samples were analyzed by immunoblot with the indicated antibodies or visu-
alized by Coomassie blue staining. gp78c represents the cytosolic domain (aa 308–643) of gp78. The results shown in (B), (D), (E), and (F) are rep-
resentative of three to four independent experiments.118 Cell Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc.
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRFigure 3. Ufd1 Enhances the Ubiquitination and Degradation of HMG-CoA Reductase
(A and B) Six hours after transfection, CHO-7 cells were depleted of sterols by incubating for 16 hr at 37C in medium A containing 5% LPDS, 10 mM
compactin, and 10 mM mevalonate. Cells were then switched to medium A containing 5% LPDS, 10 mM compactin, and 10 mM MG132 in the absence
() or presence (+) of 1 mg/ml 25-hydroxycholesterol (25-HC). Following the indicated incubation time, cells were harvested, lysed, and subjected
sequentially to immunoprecipitation with the indicated antibodies.
(C) CHO-7 cells were transfected and subsequently depleted of sterols as described in Figure 3A. Sterol-depleted cells were switched to medium A
containing 5% LPDS and 10 mM compactin in the absence () or presence (+) of 1 mg/ml 25-HC plus 10 mM mevalonate. Following incubation for 5 hr
at 37C, cells were harvested, lysed, and subjected to immunoblot analysis with the indicated antibodies.
(D) SV-589 cells were transfected with the indicated siRNA as described in Experimental Procedures. Twenty-four hours later, the cells were depleted
of sterols by incubating for 16 hr at 37C in medium B containing 10% LPDS, 50 mM compactin, and 50 mM mevalonate. Cells were then switched to
medium B containing 10% LPDS, 50 mM compactin, and 10 mM MG132 in the absence () or presence (+) of 0.1 mg/ml 25-HC as indicated. After 1 hr of
incubation, cells were harvested, lysed, and subjected sequentially to immunoprecipitation with anti-HMG-CoA reductase antibody and immunoblot
analysis with the indicated antibodies.
Results shown are representative of four independent experiments.et al., 2003). This degradation was significantly acceler-
ated when Ufd1 was overexpressed (compare lanes 8
and 6), consistent with the notion that Ufd1 increases
the ubiquitination of reductase.
The requirement of Ufd1 for sterol-dependent ubiquiti-
nation of endogenous HMG-CoA reductase was next
addressed by reducing the expression of Ufd1 by RNAi.
Human SV-589 fibroblast cells were transfected with con-Celltrol siRNA or siRNA against Ufd1. Sterol-depleted cells
were treated with or without 25-HC in the presence of
MG132 for 1 hr. HMG-CoA reductase was then im-
munoprecipitated, and its ubiquitination was analyzed.
In control-transfected cells, 25-HC induced the ubi-
quitination of reductase (Figure 3D, top panel, lane 2).
When siRNA targeting Ufd1 was introduced into cells,
the 25-HC-regulated ubiquitination of reductase wasMetabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 119
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRFigure 4. gp78- and Ubiquitin-Binding Domains in Ufd1 Are Required for Ufd1’s Function in the Sterol-Regulated ERAD of
HMG-CoA Reductase
(A and C) CHO-7 cells were transfected, treated as described in Figure 3A, harvested, lysed, and subjected sequentially to immunoprecipitation with
anti-T7 (against HMG-CoA reductase) and immunoblot analysis with the indicated antibodies.
(B and D) CHO-7 cells were transfected, treated as described in Figure 3C, harvested, lysed, and subjected to immunoblot analysis with the indicated
antibodies.
(E) E1, UBE2G2, Ufd1, Npl4, VCP, and GST-gp78c proteins were separately generated in bacteria and purified. In vitro ubiquitination assay was car-
ried out at 37C for 30 min as described in Experimental Procedures. The reactions were stopped by boiling and subjected to immunoblot assays or
visualized by Coomassie blue staining.120 Cell Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc.
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRdramatically decreased (Figure 3D, top panel, compare
lanes 4 and 2). Immunoblotting revealed that Ufd1 expres-
sion was substantially reduced by RNAi (Figure 3D, third
panel, lanes 3 and 4). As a control, the amount of actin pro-
tein in different samples was similar, regardless of sterol
treatment or siRNA transfection (Figure 3D, bottom panel,
lanes 1–4).
gp78- and Ubiquitin-Binding Domains of Ufd1 Are
Required for Its Function
To address whether the binding between Ufd1 and gp78 is
required for the effect of Ufd1 on the ubiquitination and
degradation of HMG-CoA reductase, we transfected cells
with constructs encoding Ufd1 or Ufd1(D258–275), which
does not bind to gp78. As shown in Figure 4A, the ubiqui-
tination of reductase was increased by Ufd1 (Figure 4A,
lane 3), but not Ufd1(D258–275) (Figure 4A, lane 4). Simi-
larly, Ufd1, but not Ufd1(D258–275), accelerated sterol-
stimulated degradation of reductase (Figure 4B, compare
lanes 2, 4, and 6).
The aa 8–119 region of Ufd1 has been reported to con-
stitute the ubiquitin-binding domains (Park et al., 2005).
We constructed Ufd1(D8–119) and tested it in transfection
experiments. Ufd1(D8–119) blocked the ubiquitination
and degradation of reductase stimulated by 25-HC
when it was cotransfected with Insig-1 and reductase
(Figure 4C, lane 3; Figure 4D, lanes 3 and 4). However,
Ufd1(D8–119&D258–275) lacking the gp78-binding site
(aa 258–275) failed to block the ubiquitination and degra-
dation of reductase (Figure 4C, lane 4; Figure 4D, lanes 5
and 6). Taken together, these data indicate that binding to
gp78 is a prerequisite for Ufd1 to regulate the sterol-regu-
lated ubiquitination and degradation of reductase. Ufd1
that lacks the gp78-binding site exhibits the effect of
loss of function.
Ufd1 Enhances the E3 Activity of gp78 In Vitro
A well-established function of Ufd1 is to escort ubiquiti-
nated proteins to the proteasome for degradation (Bays
and Hampton, 2002). However, we observed that Ufd1
can enhance the ubiquitination of reductase in vivo. This
raises the possibility that Ufd1 may enhance the intrinsic
E3 activity of gp78 directly by their interaction. To exclude
the postubiquitination activity of Ufd1 and test this possi-
bility directly, we analyzed the effect of Ufd1 on the E3 ac-
tivity of gp78 in an in vitro ubiquitination system containing
purified recombinant E1, UBE2G2, gp78c, and ubiquitin.
As shown in Figure 4E, gp78c catalyzed ubiquitin ladder
formation in vitro (lane 1). The reaction was enhanced by
Ufd1 protein in a concentration-dependent manner (Fig-
ure 4E, lanes 2–4). In contrast, recombinant Npl4 and VCP
had no effect on the ubiquitination reaction (Figure 4E,
lanes 5–10).CellHERP is a short-lived ER-associated protein that inter-
acts with gp78. The cytosolic domain of HERP (HERPc)
can be efficiently ubiquitinated by gp78 in vitro (Li et al.,
2007). To further determine whether Ufd1 increases
gp78-mediated substrate ubiquitination, we purified the
HERPc protein and tested it in the in vitro ubiquitination
assay. As shown in Figure 4F, Ufd1 itself had no effect
(lane 3), but it greatly enhanced the polyubiquitination of
HERPc protein in the presence of gp78c in vitro (compare
lanes 2 and 1). Thus, our data clearly demonstrate that
Ufd1 directly promotes ubiquitin ladder formation and
substrate ubiquitination catalyzed by gp78.
The Monoubiquitin-Binding Site of Ufd1 Is Required
to Enhance the E3 Activity of gp78
Previous work has illustrated that the ubiquitin-binding
domain of Ufd1 encompasses the first 119 residues and
is required for the dislocation process during ERAD
(Park et al., 2005; Ye et al., 2003). It has been proposed
that Ufd1 binds to the polyubiquitin chains on ERAD
substrates by this domain and further mediates the post-
ubiquitination reaction (Ye et al., 2003). However, recent
structural studies of Ufd1 using NMR have revealed that
Ufd1 has distinct binding sites for monoubiquitin and
polyubiquitin chains within the first 119 residues (Walters,
2005; Park et al., 2005). The functions of the ubiquitin-
binding sites in Ufd1 are largely unknown. Since our
results revealed a function of Ufd1 to activate gp78, we
next tested the roles of both ubiquitin-binding sites in
our ubiquitination and degradation assays.
Based on the identified mono- and polyubiquitin-
binding sites in Ufd1 (Park et al., 2005), we constructed
Ufd1 mutants that carried mutations on the individual
sites. Their effects on the ubiquitination of HMG-CoA
reductase in intact cells were measured. As shown in
Figure 5A, wild-type Ufd1 (Ufd1(WT)) significantly in-
creased the ubiquitination of reductase (lane 3). The
Ufd1 mutant carrying mutations on the monoubiquitin-
binding site (Ufd1(MUB Mut)) decreased the sterol-
induced ubiquitination of reductase (Figure 5A, lane 4).
In contrast, the mutant Ufd1 lacking the polyubiquitin-
binding site (Ufd1(PUB Mut)) dramatically increased the
ubiquitination of reductase (Figure 5A, lane 5), as
Ufd1(WT) did (Figure 5A, lane 3).
An in vitro ubiquitination assay was then carried out to
measure the effects of the mutant Ufd1 proteins on the
E3 activity of gp78. Similarly, Ufd1(WT) and Ufd1(PUB
Mut) strongly enhanced the ubiquitination reaction in
a concentration-dependent manner (Figure 5B, lanes 2–
4, 7, and 8), but Ufd1(MUB Mut) failed to increase the ubiq-
uitination reaction (Figure 5B, lanes 5 and 6). These data
demonstrate that the monoubiquitin-binding site of Ufd1
is required for the enhancement of the E3 activity of gp78.(F) In vitro ubiquitination reactions in which 0.3 mg HERPc-Myc and 0.3 mg/ml Ufd1 protein were applied were performed as described in Figure 4E.
After 30 min of reaction, the mixtures were diluted, immunoprecipitated with anti-Myc (against HERPc), and immunoblotted with the indicated anti-
bodies.
Results shown are representative of three to four independent experiments.Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 121
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Ufd1 Binds to gp78 and Promotes the ERAD of HMGCRFigure 5. The Monoubiquitin-Binding Site of Ufd1 Is Required for Enhancing the E3 Activity of gp78
(A) CHO-7 cells were transfected, treated, and processed as described in Figure 3A, and immunoblots were performed with the indicated antibodies.
MUB Mut, monoubiquitin-binding site mutant; PUB Mut, polyubiquitin-binding site mutant.
(B) In vitro ubiquitination assay was carried out as described in Figure 4E, and the reaction mixtures were analyzed by immunoblot with the indicated
antibodies. The asterisk denotes a degraded band.
(C) CHO-7 cells were transfected, treated, and processed as described in Figure 3C, and immunoblots were performed with the indicated antibodies.
The asterisk denotes a crossreactive band.
Results shown are representative of three independent experiments.We next tested the effects of these Ufd1 mutants on the
sterol-regulated degradation of HMG-CoA reductase.
Ufd1(WT) accelerated the sterol-induced degradation of
reductase (Figure 5C, lane 4). Strikingly, this degradation
was blocked by either Ufd1(MUB Mut) or Ufd1(PUB Mut)
(Figure 5C, lanes 6 and 8). Taken together, these data
indicate that Ufd1(PUB Mut) lacking the polyubiquitin-
binding site enhances ubiquitination but blocks degrada-
tion of reductase, indicating that the polyubiquitin-binding
site of Ufd1 is required for a postubiquitination step in
ERAD of reductase.
Ufd1 Regulates the Cellular Uptake of LDL
HMG-CoA reductase is the rate-limiting enzyme in the
cholesterol synthesis pathway and is tightly regulated.
When its activity or protein amount is decreased, cellular
cholesterol concentration is downregulated and the
compensatory sterol regulatory element-binding pro-
tein (SREBP) pathway is activated. The nuclear form of
SREBP (nSREBP) is increased, and the expression of122 Cell Metabolism 6, 115–128, August 2007 ª2007 ElsevierLDL receptor is in turn upregulated, which leads to a com-
pensatory increase of cholesterol absorption (Brown and
Goldstein, 1999). Since Ufd1 plays important roles in the
degradation of HMG-CoA reductase (Figures 3–5), we hy-
pothesized that overexpression of Ufd1 would accelerate
reductase degradation, decrease cholesterol synthesis,
increase nSREBPs, and ultimately enhance the uptake
of LDL through elevating the expression of LDL receptor
(Brown and Goldstein, 1999). To test this hypothesis, we
made a cell line stably overexpressing Ufd1. In this cell
line, reductase protein was decreased (Figure 6A, top
panel) and nuclear SREBP-1 and -2 were increased (sec-
ond and third panels). To test whether the activation of
SREBPs causes a functional increase of LDL receptor,
we performed LDL uptake assays. There was a remarkable
increase in the intensity of intracellular fluorescence (fluo-
rescently labeled LDL uptake) in Ufd1-overexpressing
cells compared with control cells (Figure 6B, red signal).
Quantification revealed that the LDL uptake was in-
creased by about 4-fold when Ufd1 was overexpressed.Inc.
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(A) Lysates of CHO-7 and CHO-7/Ufd1 cells stably overexpressing Ufd1 were blotted with the indicated antibodies.
(B) CHO-7 and CHO-7/Ufd1 cells were placed in fresh media supplemented with fluorescently labeled low-density lipoprotein (DiI-LDL, red) for 2 hr
and then washed, fixed, and examined by fluorescence microscopy. Nuclei were stained with Hoechst (blue). Photographs were taken using identical
exposure times and camera settings.
(C) Quantification of the cellular DiI-LDL fluorescence signals as shown in (B).
(D) Lysates of SV-589 cells transfected with control or Ufd1 siRNA were blotted with the indicated antibodies.
(E) SV-589 cells were transfected with control or Ufd1 siRNA for 48 hr. Receptor-mediated uptake of DiI-LDL was analyzed as described in (B).
(F) Quantification of the cellular DiI-LDL fluorescence signals as shown in (E).
Results shown are representative of three independent experiments.Similar results were also obtained from multiple indepen-
dent cell clones stably overexpressing Ufd1 protein (data
not shown).
To further exclude the variations of individual stable cell
clones, we transfected CHO-7 cells with mock or FLAG-
Ufd1-encoding plasmids. Following selection by G418,
we obtained the cell mixture stably expressing Ufd1. The
cell populations were then supplied with fluorescently la-
beled LDL (DiI-LDL) to analyze the uptake of LDL. As
shown in Figure S3, the intensity of intracellular fluores-
cence in cells stably expressing Ufd1 was much stronger
than that in control cells.
Meanwhile, we measured LDL uptake in Ufd1-RNAi
cells. Figure 6D shows that Ufd1 was efficiently knocked
down by RNAi (compare lanes 2 and 1). In contrast to
Ufd1-overexpressing cells, the uptake of fluorescently la-
beled LDL was dramatically decreased in Ufd1-RNAi cells
(Figure 6E, red signal). This result is consistent with the
data from the Ufd1 overexpression experiment and dem-
onstrates that Ufd1 modulates the uptake of LDL through
regulating the stability of reductase.CeIn summary, our data demonstrate that Ufd1 directly in-
teracts with gp78 and functions as a cofactor. Through
enhancing gp78 activity and mediating the postubiquitina-
tion step, Ufd1 increases the sterol-stimulated ubiquitina-
tion and degradation of HMG-CoA reductase, thereby
upregulating the receptor-mediated clearance of LDL.
DISCUSSION
The Direct Interaction between gp78 and Ufd1
Previous studies have found that VCP is capable of bind-
ing to Ufd1 or gp78 (Zhong et al., 2004; Meyer et al., 2000;
Song et al., 2005b). Here, we provide strong evidence
showing that the direct interaction between Ufd1 and
gp78 is not bridged by VCP. First, the Ufd1-binding region
(aa 383–497) in gp78 is different from the VCP-interacting
motif (VIM, aa 614–643) (Ballar et al., 2006; Zhong et al.,
2004). A gp78 mutant without the VIM can still bind to
Ufd1 (Figure 2B). Second, gp78 and VCP bind to Ufd1 at
different sites (Figure 2C) (Bruderer et al., 2004). A mutant
of Ufd1 lacking the VCP-binding site can still interact withll Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 123
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to Ufd1 is unaffected by VCP RNAi (Figure S1). Finally,
Ufd1 directly binds to gp78, as demonstrated by in vitro
GST pull-down assays in which VCP was absent (Figures
2E and 2F). These results exclude the possibility that VCP
mediates the interaction between Ufd1 and gp78.
We have mapped the interacting regions on gp78 and
Ufd1 by coIP and in vitro pull-down assays. Interestingly,
the gp78-binding region in Ufd1 (residues 258–275) over-
laps with the reported Npl4-binding site (Bruderer et al.,
2004). The VCP-Ufd1-Npl4 complex has been widely
studied and has been shown to play an important role in
ERAD. Therefore, we performed further experiments to
test the competition between Npl4 and gp78 for Ufd1
binding. The results showed that gp78 and Npl4 bind to
Ufd1 in a mutually exclusive manner (Figure S4). Taken
together, our data suggest that Ufd1 binds to gp78 by it-
self and that the gp78-activating function of Ufd1 is inde-
pendent of Npl4 and VCP. Furthermore, it is possible that
Npl4 and VCP may also conduct important functions by
themselves.
Recently, Ballar et al. (2006) showed that VCP cannot
bridge the interaction between gp78 and Ufd1. This find-
ing is consistent with our finding that gp78 directly binds
to Ufd1. However, in their study, Ballar et al. did not detect
the association between gp78 and Ufd1. We reason that
this discrepancy most likely reflects differences in the ratio
of gp78 to Ufd1 used in two study systems. In the present
work, we detected the interaction between endogenous
gp78 and Ufd1, as well as that between the cotransfected
proteins (Figure 1; Figure 2; Figure S1). However, Ballar
et al. used cells overexpressing gp78 and one of its sub-
strates, CD3d. Therefore, endogenous Ufd1 may not be
sufficient to bind both endogenous and exogenous
gp78. This may also explain their observation that Ufd1
is dispensable for the degradation of CD3d in cells overex-
pressing gp78 but required for that in cells expressing
endogenous levels of gp78.
Ufd1 Is a Cofactor of the Ubiquitin Ligase gp78
Ubiquitination is carried out through the sequential actions
of three types of enzymes: the ubiquitin-activating enzyme
(E1), ubiquitin-conjugating enzymes (E2s), and ubiquitin
ligases (E3s). Ubiquitin is first covalently conjugated to
a reactive cysteine residue of E1 (E1-Ub) and is then trans-
ferred to a catalytic cysteine of E2 (E2-Ub). Finally, E3
facilitates the transfer of ubiquitin from E2-Ub to a lysine
residue on the substrate (or ubiquitin) (Pickart, 2001;
Hershko et al., 2000). This reaction can be repeated
several times to form polyubiquitin chains. The substrate
specificity is usually determined by E3. Occasionally,
a specialized E3 ubiquitin ligase, E4 enzyme, elongates
ubiquitin chains of oligoubiquitinated proteins to generate
polyubiquitin conjugates from oligoubiquitinated precur-
sors (Hoppe, 2005).
Interestingly, Ufd1 significantly increases polyubiquiti-
nation in vivo and in vitro (Figure 3 and Figure 4). What is
the mechanism of Ufd1 in these events? One possibility
is that Ufd1 works as an E4 that elongates the ubiquitin124 Cell Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inchains initiated by gp78. However, Ufd1 does not catalyze
the formation of polyubiquitin chains by itself in vitro
(Figure 4F and data not shown). This piece of evidence
suggests that Ufd1 is not an E4. On the other hand,
gp78 directly interacts with Ufd1 (Figure 1 and Figure 2),
and the enhancement of gp78-catalyzed polyubiquitina-
tion by Ufd1 is dependent on their interaction (Figure 4),
indicating that Ufd1 functions as a cofactor of gp78.
There are two main classes of cofactors of E3. In some
cases, the cofactors help to recruit substrates. These
cofactors bind E3 and substrates simultaneously. For
example, Cdc20 bridges the E3 anaphase-promoting
complex to its substrates, including cyclin B (Yu, 2002;
Hershko, 1999). The other class of cofactors function di-
rectly to increase the intrinsic activity of their interacting
E3. They do not necessarily bind substrates directly. For
instance, as Mdm2’s cofactor, Daxx is found to enhance
the E3 activity of Mdm2 (Tang et al., 2006). In our case,
Ufd1 directly increases the activity of gp78, and this effect
is dependent on its monoubiquitin-binding site (Figure 5).
Studying whether Daxx binds monoubiquitin and whether
this binding is required for its function will be interesting
and will provide further insights.
During the reviewing of this paper, Li et al. (2007) pub-
lished their study showing that gp78 first catalyzes forma-
tion of a polyubiquitin chain on UBE2G2 and then transfers
the preassembled ubiquitin chain to a substrate. As a co-
factor, Ufd1 can theoretically be involved in either of these
steps. However, the data in Figure 4E show that Ufd1
enhances ubiquitin ladder formation in a substrate-free
system in vitro, suggesting that Ufd1 may promote the first
step in gp78-catalyzed reactions. We further tested the
effect of Ufd1 on the polyubiquitin assembly on E2 and
found that Ufd1 dramatically enhanced this assembly in
a concentration-dependent manner (Figure S5, lanes 1
to 3). Therefore, our data support the notion that Ufd1
facilitates gp78 in catalyzing the polyubiquitin chain
formation on UBE2G2.
The Mechanisms for Ufd1 Enhancing the E3 Activity
of gp78
How does Ufd1 increase the E3 activity of gp78? One pos-
sibility is that Ufd1 helps gp78 to recruit E2-Ub. In the
ubiquitin ligation reaction, the E3 enzyme utilizes the E2-
Ub conjugate as a ubiquitin donor (Hershko et al., 2000;
Pickart, 2001). Previous studies have demonstrated that
UBE2G2 is the E2 for gp78 (Fang et al., 2001; Chen
et al., 2006). The G2BR domain of gp78 (Figure 2A) is
responsible for UBE2G2 binding (Chen et al., 2006).
Meanwhile, the monoubiquitin-binding site of Ufd1 inter-
acts with ubiquitin. Therefore, UBE2G2-Ub may bind
gp78-Ufd1 at these two different sites at the same time.
This bivalent interaction may synergistically increase the
affinity of UBE2G2-Ub to the gp78-Ufd1 complex. Consis-
tently, both monoubiquitin- and gp78-binding sites in Ufd1
are required for the enhancement of gp78 activity (Figure 4
and Figure 5).
Recently, there have been significant discoveries show-
ing that Cdc48 (the yeast homolog of VCP) associates withc.
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of Ufd1 in Sterol-Regulated Degradation
of HMG-CoA Reductase
Sterol stimulates the ER-associated degrada-
tion of HMG-CoA reductase by promoting the
binding between reductase and the Insig-
gp78-VCP complex. Through direct interaction
with gp78, Ufd1 participates in this process
and plays a dual role: (1) increasing the ubiqui-
tination reaction that requires the monoubiqui-
tin-binding site in Ufd1, and (2) accelerating the
postubiquitination step that is dependent on
the polyubiquitin-binding site in Ufd1. Mutation
of either the mono- or polyubiquitin-binding
site in Ufd1 can block the degradation of
reductase.Ufd2, an E4, to accelerate substrate ubiquitination and
degradation during ERAD (Richly et al., 2005; Rumpf and
Jentsch, 2006; Koegl et al., 1999). It was found that Ufd2
is recruited to the ERAD substrates by the Cdc48-Ufd1-
Npl4 complex through its direct interaction with Cdc48
and further polyubiquitinates the substrates, which even-
tually leads to proteasomal degradation (Koegl et al.,
1999). Although we have demonstrated that Ufd1 directly
enhances the E3 activity of gp78 in vitro (Figures 4E and
4F; Figure 5B; Figure S5), it is still possible that Ufd1 brings
VCP-Ufd2 to the gp78 complex, which leads to the in-
creasing of reductase ubiquitination in intact cells. If this
is the case, reducing Ufd1 should diminish gp78-VCP in-
teraction, and knocking down VCP should attenuate the
ubiquitination of HMG-CoA reductase. To test this hy-
pothesis, we first detected the gp78-VCP interaction by
coIP upon Ufd1 RNAi. Our results showed that the VCP
protein coimmunoprecipitated with gp78 was unaffected
by reducing Ufd1 level (Figure S6A), indicating that Ufd1
does not bring VCP to gp78. Consistent with the notion
that gp78 and Ufd1 bind VCP in a mutually exclusive man-
ner (Ballar et al., 2006), the VCP and Ufd1 proteins may in-
teract with gp78 independently. Next, we analyzed the
sterol-regulated ubiquitination of reductase after knocking
down VCP by RNAi. As shown in Figure S6B, the ubiquiti-
nation of reductase was similar in the presence or ab-
sence of VCP. Taken together, our results do not support
the hypothesis that Ufd1 enhances the ubiquitination of
reductase in vivo by recruiting VCP-Ufd2.
It has been demonstrated in yeast that Cdc48 is capable
of recruiting different cofactors (including Ufd2, Ufd3, and
Otu1) to modulate the ubiquitination status of its sub-
strates and determine their destinations (Rumpf and
Jentsch, 2006). However, it is currently unknown how
the central role of Cdc48 in ERAD is regulated under phys-
iological conditions. Substrate selectivity may exist, andCellVCP is possibly involved in the ERAD of unfolded proteins
other than sterol-regulated degradation of HMG-CoA
reductase.
Dual Functions of Ufd1 in the ERAD of HMG-CoA
Reductase
There are two ubiquitin-binding sites in Ufd1: the mono-
and polyubiquitin-binding sites (Park et al., 2005). Muta-
tion of the monoubiquitin-binding site blocks both the
ubiquitination and degradation of HMG-CoA reductase.
On the other hand, mutation of the polyubiquitin-binding
site enhances the ubiquitination but blocks degradation
of reductase (Figure 5).
According to our results, we propose a model illustrat-
ing the key functions of Ufd1 in the sterol-induced ERAD
of HMG-CoA reductase, depicted in Figure 7. The process
is initiated by the sterol-promoted binding between reduc-
tase and Insig in the membrane, which recruits the Insig-
associated E3 gp78. gp78 catalyzes the ubiquitination of
reductase at specific lysine residues. Ufd1 is also brought
into this complex by its interaction with gp78 and performs
its first role here, enhancing the E3 activity of gp78 through
monoubiquitin binding. After ubiquitination, the modified
reductase is degraded by the proteasome. At this step,
Ufd1 plays its second role, mediating the postubiquitina-
tion step that is dependent on the polyubiquitin-binding
site. Therefore, Ufd1 plays a dual role in the sterol-
regulated degradation of reductase.
As an ER membrane-anchored ubiquitin ligase, gp78
mediates not only the sterol-regulated degradation of
HMG-CoA reductase but also the degradation of other
substrates, such as misfolded proteins. Our results reveal
that Ufd1 is a cofactor of gp78 and plays a dual role in ste-
rol-induced ERAD of HMG-CoA reductase. We further
found that Ufd1 also accelerates the degradation of In-
sig-1 (Figure S7), another substrate of gp78 (Lee et al.,Metabolism 6, 115–128, August 2007 ª2007 Elsevier Inc. 125
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ERAD of other gp78 substrates, including CD3d (Fang
et al., 2001), ApoB-100 (Liang et al., 2003), and a-1-
antitrypsin (Shen et al., 2006). The direct interaction
between gp78 and Ufd1 ensures effective ubiquitination
and couples the ubiquitination step to the postubiquitina-
tion step. This discovery represents a configuration that
assures the efficiency of the ERAD process.
Upregulation of Ufd1 May Be Beneficial for
Hypercholesterolemia Patients
Cardiovascular disease is highly correlated with elevated
level of plasma LDL cholesterol. The most common treat-
ment for elevated cholesterol levels in humans is a group
of drugs called statins that competitively inhibit the en-
zyme activity of HMG-CoA reductase. The inhibition of
reductase activity by statins results in depletion of liver
cholesterol, which promotes the maturation of nSREBPs.
nSREBPs in turn activate transcription of the LDL receptor
gene, thereby increasing receptor-mediated clearance
of LDL (Brown and Goldstein, 1999). At the same time,
statins elevate the amount of HMG-CoA reductase, which
becomes progressively harder to inhibit (Kita et al., 1980;
Singer et al., 1984).
This compensatory increase of reductase can be re-
duced by accelerating its degradation. Our research on
the mechanism of sterol-regulated degradation of reduc-
tase provides important insights and potential drug
targets for designing more effective therapies. We have
demonstrated that elevating the expression of Ufd1
decreases levels of reductase and eventually causes an
increase of the receptor-mediated uptake of LDL. Thus,
Ufd1 and its interaction with gp78 may present attractive
targets when developing new cholesterol-lowering thera-
pies. Importantly, we have found that the binding of Ufd1
to gp78 is significantly potentiated by sterol and mevalo-
nate (Figure S8). The mechanism of this regulated interac-
tion is currently under intensive investigation.
In conclusion, we have elucidated that Ufd1 directly
binds to gp78 and potentiates its E3 activity toward
HMG-CoA reductase, therefore regulating the receptor-
mediated uptake of LDL. In addition, as a cofactor of
gp78, Ufd1 has a dual role in gp78-promoted ER-
associated degradation: increasing E3 activity that is
dependent on the monoubiquitin-binding site and mediat-
ing the postubiquitination step that requires the polyubi-
quitin-binding site in Ufd1.
EXPERIMENTAL PROCEDURES
A complete description of materials, plasmids, cell culture, primary
antibodies, recombinant protein purification, and other methods is
available in the Supplemental Experimental Procedures.
Coimmunoprecipitation
Cells were harvested and lysed in 0.5 ml of PBS containing 0.1% NP-
40 (v/v), 5 mM EDTA, 5 mM EGTA, 20 mM leupeptin, 25 mg/ml ALLN,
5 mg/ml pepstatin A, and 2 mg/ml aprotinin and clarified by centrifuga-
tion at 100,000 3 g for 10 min at 4C. Immunoprecipitation with anti-126 Cell Metabolism 6, 115–128, August 2007 ª2007 Elsevier Ibody-coupled agarose beads was carried out as described previously
(Sever et al., 2003).
GST Pull-down Assay
GST fusion proteins were immobilized on glutathione agarose beads;
blocked with PBS containing 0.1% NP-40 (v/v), 5 mM EDTA, 5 mM
EGTA, 20 mM leupeptin, 25 mg/ml ALLN, 5 mg/ml pepstatin A, and
2 mg/ml aprotinin plus 5% nonfat milk; and incubated with the indicated
proteins for 2 hr at 4C. After washing five times, the bound proteins
were dissolved in SDS sample buffer, separated by SDS-PAGE, and
subjected to immunoblot assays.
In Vitro Ubiquitination Assay
Standard ubiquitination reactions were performed in 100 ml volume
containing 25 mM HEPES (pH 7.4), 10 mM NaCl, 3 mM MgCl2,
0.05% Triton X-100, 0.5 mM DTT, 3 mM Mg-ATP, 3 mg E1, 0.3 mg
UBE2G2, 10 mg ubiquitin (Ub) or FLAG-Ub, 0.3 mg cytosolic domain
of gp78 (gp78c, aa 308–643), and the indicated concentration of vari-
ous Ufd1 proteins or HERPc protein. Reaction mixtures were incu-
bated at 37C for the indicated time.
LDL Uptake Assays
Cells grown on coverslips were incubated with medium A containing
5% LPDS and 10 mg/ml of fluorescently labeled LDL (DiI-LDL) (Invitro-
gen) for 2 hr, washed, and fixed in 4% paraformaldehyde in PBS for
20 min at room temperature. The cells were subsequently washed in
PBS, and nuclei were stained with Hoechst. Intracellular fluorescent
dye was detected by a 403 objective on an Olympus BX51 micro-
scope. Images were acquired at identical exposure times and camera
settings and quantified using Image-Pro Plus software. The total fluo-
rescence intensity was divided by the number of cells in the same field
to give the average intensity. The average intensity of control cells was
defined as 100%.
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures,
Supplemental References, and eight figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/
6/2/115/DC1/.
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